MedPath

ASPRUZYO SPRINKLE

These highlights do not include all the information needed to use ASPRUZYO SPRINKLE safely and effectively. See full prescribing information for ASPRUZYO SPRINKLE.ASPRUZYO SPRINKLE (ranolazine) extended-release granules, for oral useInitial U.S. Approval: 2006

Approved
Approval ID

dd9f81e4-50da-4551-aed5-559d304df42e

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Mar 2, 2022

Manufacturers
FDA

SUN PHARMACEUTICAL INDUSTRIES, INC.

DUNS: 146974886

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ranolazine

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code47335-624
Application NumberNDA216018
Product Classification
M
Marketing Category
C73594
G
Generic Name
Ranolazine
Product Specifications
Route of AdministrationORAL
Effective DateMarch 2, 2022
FDA Product Classification

INGREDIENTS (9)

MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
ETHYLCELLULOSE, UNSPECIFIEDInactive
Code: 7Z8S9VYZ4B
Classification: IACT
RANOLAZINEActive
Quantity: 500 mg in 1 1
Code: A6IEZ5M406
Classification: ACTIB
DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMERInactive
Code: 905HNO1SIH
Classification: IACT
DIBUTYL SEBACATEInactive
Code: 4W5IH7FLNY
Classification: IACT
HYPROMELLOSE, UNSPECIFIEDInactive
Code: 3NXW29V3WO
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT
METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE AInactive
Code: NX76LV5T8J
Classification: IACT

Ranolazine

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code47335-625
Application NumberNDA216018
Product Classification
M
Marketing Category
C73594
G
Generic Name
Ranolazine
Product Specifications
Route of AdministrationORAL
Effective DateMarch 2, 2022
FDA Product Classification

INGREDIENTS (9)

DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMERInactive
Code: 905HNO1SIH
Classification: IACT
DIBUTYL SEBACATEInactive
Code: 4W5IH7FLNY
Classification: IACT
ETHYLCELLULOSE, UNSPECIFIEDInactive
Code: 7Z8S9VYZ4B
Classification: IACT
HYPROMELLOSE, UNSPECIFIEDInactive
Code: 3NXW29V3WO
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE AInactive
Code: NX76LV5T8J
Classification: IACT
RANOLAZINEActive
Quantity: 1000 mg in 1 1
Code: A6IEZ5M406
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ASPRUZYO SPRINKLE - FDA Drug Approval Details